OMER
OMEROS CORPCompany Information
- Company Name
- OMEROS CORP
- CIK
- CIK0001285819
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- OMER: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- OMER
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-11-17
- Last sale
- 2026-09-23
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 103,406
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 32,713,629
- Shares outstanding
- 72,131,526
- Ownership
- 45.35%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- 38.22%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Cash Equivalents At Carrying Value | 2 | 2 | 10 | 2 | 2 | 4 | 3 | 2 | 2 | 2 | 7 | 31 | ||||||
| Short Term Investments | 130 | 133 | 162 | 34 | 27 | 48 | 87 | 122 | 157 | 229 | 165 | 280 | ||||||
| Receivables Net Current | 21 | 12 | 11 | 7 | 6 | 7 | 8 | 6 | 8 | 8 | 8 | 7 | ||||||
| Inventory Net | 1 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 185 | 180 | 216 | 72 | 70 | 96 | 134 | 165 | 203 | 281 | 218 | 351 | ||||||
| Prepaid Expense And Other Assets Current | 6 | 7 | 8 | 4 | 6 | 7 | 7 | 6 | 6 | 13 | 9 | 5 | ||||||
| Operating Lease Right Of Use Asset | 8 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 19 | ||||||
| Property Plant And Equipment Net | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | ||||||
| Restricted Cash And Cash Equivalents Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 287 | 286 | 326 | 186 | 201 | 235 | 277 | 313 | 356 | 437 | 378 | 493 | ||||||
| Accounts Payable Current | 6 | 5 | 5 | 12 | 9 | 4 | 6 | 8 | 7 | 6 | 8 | 6 | ||||||
| Accrued Liabilities Current | 29 | 28 | 29 | 26 | 26 | 25 | 26 | 23 | 28 | 28 | 32 | 35 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 95 | 59 | 78 | 81 | 86 | 83 | 80 | 56 | 59 | 59 | 53 | 147 | ||||||
| Senior Notes Current | 0 | 0 | 17 | 17 | 17 | 27 | 0 | - | - | - | 0 | 95 | ||||||
| Loans Payable Current | - | - | 0 | 0 | 0 | 0 | 21 | - | - | - | - | - | ||||||
| Shares Subject To Mandatory Redemption Settlement Terms Amount Current | - | - | - | - | 8 | - | - | - | - | - | - | - | ||||||
| Senior Long Term Notes | 42 | 53 | 51 | 72 | 63 | 70 | 97 | 97 | 97 | 213 | 213 | 222 | ||||||
| Long Term Loans Payable | - | - | 0 | 87 | 87 | 89 | 70 | 92 | 95 | - | 0 | - | ||||||
| Derivative Liabilities Noncurrent | 55 | 84 | - | - | - | - | - | - | - | - | - | - | ||||||
| Other Accrued Liabilities Noncurrent | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 3 | 2 | 2 | 2 | 0 | ||||||
Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Additional Paid In Capital Common Stock | - | - | - | - | - | - | - | 724 | 722 | 719 | 728 | 730 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | -51 | -63 | -121 | -220 | -229 | -214 | -183 | -154 | -125 | -71 | -25 | -14 | ||||||
| Additional Paid In Capital | 792 | 794 | 792 | 779 | 740 | 730 | 727 | - | - | - | 728 | - | ||||||
| Retained Earnings Accumulated Deficit | -844 | -858 | -914 | -1,000 | -969 | -944 | -910 | -879 | -847 | -791 | -754 | -744 | ||||||
| Liabilities And Stockholders Equity | 287 | 286 | 326 | 186 | 201 | 235 | 277 | 313 | 356 | 437 | 378 | 493 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Shares Outstanding | 72 | 72 | 72 | 70 | 60 | 58 | 58 | 58 | 58 | 58 | 61 | 63 | ||||||
| Common Stock Shares Issued | 72 | 72 | 72 | 70 | 60 | 58 | 58 | 58 | 58 | 58 | 61 | 63 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialOMEROS CORP (OMER) — SEC Financial Statements & Analysis
OMEROS CORP (OMER) is a pharmaceutical preparations company, incorporated in WA. OMEROS CORP trades on Nasdaq as: OMER. OMEROS CORP (OMER)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, OMEROS CORP carries a market cap of $685.97M, a P/E ratio of 5.50x, a P/B ratio of -13.36x, a P/S ratio of 17.85x, an enterprise value of $683.98M, and an EV/EBITDA multiple of -9.51x. On profitability, it posts an operating margin of -189.53%, a net margin of 324.88%, a Return on Equity (ROE) of -89.15%, and a Return on Assets (ROA) of 51.22%. Per share, it reports EPS of $1.73, diluted EPS of $1.39, free cash flow per share of $-0.95, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -201.92% year-over-year and EPS growth of -182.78% year-over-year. On the balance sheet, it maintains a current ratio of 1.95x, a quick ratio of 1.88x, working capital of $90.28M, a debt-to-equity ratio of -1.85x, a debt ratio of 0.33, an interest coverage ratio of -2.05x, free cash flow of $-68.73M (TTM), and net debt of $-1.99M. Figures sourced from SEC EDGAR.
- Market Cap
- $685.97M
- P/E TTM
- 5.50x
- EPS TTM
- $1.73
- P/B TTM
- -13.36x
- ROE TTM
- -89.15%
- ROA TTM
- 51.22%
- Debt To Equity
- -1.85x
- Free Cash Flow TTM
- $-68.73M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is OMEROS CORP in?
OMEROS CORP (OMER) operates in the Pharmaceutical Preparations industry.
What exchange does OMER trade on?
OMEROS CORP (OMER) trades on the Nasdaq.
Where is OMEROS CORP incorporated?
OMEROS CORP is incorporated in WA.
When was OMEROS CORP (OMER)'s most recent SEC filing?
OMEROS CORP (OMER)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is OMER's market cap?
OMEROS CORP (OMER) has a market capitalization of $685.97M as of 2026-06-30.
What is OMER's P/E ratio?
OMEROS CORP (OMER)'s trailing twelve month P/E ratio is 5.50x as of 2026-06-30.
What is OMER's EPS (earnings per share)?
OMEROS CORP (OMER)'s trailing twelve month EPS is $1.73 as of 2026-06-30.
What is OMER's ROE (return on equity)?
OMEROS CORP (OMER)'s trailing twelve month Return on Equity (ROE) is -89.15% as of 2026-06-30.
What is OMER's ROA (return on assets)?
OMEROS CORP (OMER)'s trailing twelve month Return on Assets (ROA) is 51.22% as of 2026-06-30.
What is OMER's EV/EBITDA?
OMEROS CORP (OMER)'s trailing twelve month EV/EBITDA is -9.51x as of 2026-06-30.